Suppression of lung adenocarcinoma progression by Nkx2-1

Nkx2-1 as an oncogene and tumour-suppressor In a mouse model of lung cancer driven by activated K-Ras and p53 loss, Jacks and colleagues describe a method for tracing individual metastases back to the primary tumours, allowing non-metastatic lesions to be distinguished from metastatic lesions in the same animal. A comparison of gene-expression signatures between metastatic and non-metastatic tumours with human lung cancers led to the identification of Nkx2-1/TTF-1 as a gene that is down-regulated during tumour progression in mice, and associated with poorer outcome in patients. Nkx2-1 loss promotes metastasis at least in part by regulating Hmga2, resulting in de-differentiation. Thus Nkx2-1, previously identified as a lung-cancer oncogene, can also function as a suppressor of lung-cancer progression. Despite the high prevalence and poor outcome of patients with metastatic lung cancer the mechanisms of tumour progression and metastasis remain largely uncharacterized. Here we modelled human lung adenocarcinoma, which frequently harbours activating point mutations in KRAS 1 and inactivation of the p53 pathway 2 , using conditional alleles in mice 3 , 4 , 5 . Lentiviral-mediated somatic activation of oncogenic Kras and deletion of p53 in the lung epithelial cells of Kras LSL-G12D/+ ;p53 flox/flox mice initiates lung adenocarcinoma development 4 . Although tumours are initiated synchronously by defined genetic alterations, only a subset becomes malignant, indicating that disease progression requires additional alterations. Identification of the lentiviral integration sites allowed us to distinguish metastatic from non-metastatic tumours and determine the gene expression alterations that distinguish these tumour types. Cross-species analysis identified the NK2-related homeobox transcription factor Nkx2-1 (also called Ttf-1 or Titf1) as a candidate suppressor of malignant progression. In this mouse model, Nkx2-1 negativity is pathognomonic of high-grade poorly differentiated tumours. Gain- and loss-of-function experiments in cells derived from metastatic and non-metastatic tumours demonstrated that Nkx2-1 controls tumour differentiation and limits metastatic potential in vivo . Interrogation of Nkx2-1-regulated genes, analysis of tumours at defined developmental stages, and functional complementation experiments indicate that Nkx2-1 constrains tumours in part by repressing the embryonically restricted chromatin regulator Hmga2. Whereas focal amplification of NKX2